Prosecution Insights
Last updated: April 19, 2026
Application No. 17/609,451

DNA ENCODED IL-36 GAMMA AS AN ADJUVANT

Non-Final OA §112
Filed
Nov 08, 2021
Examiner
PARKIN, JEFFREY S
Art Unit
1671
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Wistar Institute
OA Round
3 (Non-Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
3y 7m
To Grant
85%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allow Rate
542 granted / 852 resolved
+3.6% vs TC avg
Strong +21% interview lift
Without
With
+21.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
41 currently pending
Career history
893
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
3.6%
-36.4% vs TC avg
§112
46.7%
+6.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 852 resolved cases

Office Action

§112
Detailed Office Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 37 C.F.R. § 1.114 A request for continued examination under 37 C.F.R. § 1.114, including the fee set forth in 37 C.F.R. § 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 C.F.R. § 1.114, and the fee set forth in 37 C.F.R. § 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 C.F.R. § 1.114. Status of the Claims Acknowledgement is hereby made of receipt and entry of the communication filed 18 February, 2026. Claims 1, 2, and 4-20 are pending in the instant application. Claims 11-20 stand withdrawn from further consideration by the Examiner, pursuant to 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention. 35 U.S.C. § 112(a) The following is a quotation of 35 U.S.C. § 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Written Description The previous rejection of claims 1, 2, and 4-10 under 35 U.S.C. § 112(a), as failing to comply with the written description requirement, is hereby withdrawn in response to Applicant’s amendment and arguments. 35 U.S.C. § 112(b) The following is a quotation of 35 U.S.C. § 112(b): (b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1, 2, and 4-10 are rejected under 35 U.S.C. § 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, regards as the invention. Two separate requirements are set forth under this statute: (1) the claims must set forth the subject matter that applicants regard as their invention; and (2) the claims must particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant. The claimed invention is directed toward an immunogenic composition comprising nucleic acids encoding an antigen of interest and IL-36 adjuvant. Immunogenicity is the ability of an antigen to induce an immune response (Pollard and Bijker, 2021). This recitation is vague and indefinite because the nucleic acids themselves would not necessarily be expected to be immunogenic. Amendment of the claim language to reference an immunizing composition comprising the nucleic acids of interest or a composition capable of inducing an immune response against an antigen comprising the nucleic acids of interest, would be acceptable. Correspondence Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The Examiner can normally be reached Monday through Friday from 10:00 AM to 6:00 PM. A message may be left on the Examiner's voice mail service. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the Examiner are unsuccessful, the Examiner's supervisor, Michael Allen, Ph.D., can be reached at (571) 270-3497. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Information regarding the status of an application may be obtained from the Patent Center. Status information for published applications may be obtained from the Patent Center. Status information for unpublished applications is available through the Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Respectfully, /JEFFREY S PARKIN/Primary Examiner, Art Unit 1671 07 March, 2026
Read full office action

Prosecution Timeline

Nov 08, 2021
Application Filed
Apr 13, 2025
Non-Final Rejection — §112
Aug 05, 2025
Response Filed
Nov 14, 2025
Final Rejection — §112
Feb 18, 2026
Request for Continued Examination
Feb 24, 2026
Response after Non-Final Action
Mar 07, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600955
REPLICATION-COMPETENT RECOMBINANT HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) COMPRISING DELETIONS IN THE ICP6 AND IR REGIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12582708
RECOMBINANT INFLUENZA VIRUSES COMPRISING TRUNCATED NS1 FUSION PROTEINS
2y 5m to grant Granted Mar 24, 2026
Patent 12553894
METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION
2y 5m to grant Granted Feb 17, 2026
Patent 12551549
METHODS OF ELICITING ANTIBODIES THAT BIND TO FULL-LENGTH GLYCOSYLATED HIV-1 ENV USING MULTIMERIZED ENV CORES
2y 5m to grant Granted Feb 17, 2026
Patent 12540333
CHARACTERIZATION OF IMPURITIES IN ADENO-ASSOCIATED VIRUS (AAV) SAMPLES AND FORMULATION COMPOSITIONS TO STABILIZE AAV
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
85%
With Interview (+21.2%)
3y 7m
Median Time to Grant
High
PTA Risk
Based on 852 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month